P17-17. Newborn mice vaccination with rBCG:HIVA + MVA:HIVA enhances HIV1-specific immune responses. Influence of age and immunization routes (original) (raw)
AI-generated Abstract
Background: The study evaluates the HIV-specific cellular immune responses in newborn and adult mice after immunization with rBCG:HIVA as a prime and MVA:HIVA as a boost, highlighting the importance of age and immunization routes. Methods: Adult mice (7 weeks old) received rBCG:HIVA via intradermal and subcutaneous routes, while newborn mice (7 days old) received it subcutaneously. Specific immune responses were analyzed after a boost with MVA:HIVA. Results: CD8+ T-cells producing IFN-γ were significantly higher in adult mice vaccinated intradermally compared to newborns. Newborn mice showed higher CTL activity despite lower CD8+ T-cell frequencies. Conclusion: rBCG:HIVA administration is safe for newborns and enhances HIV-specific responses induced by MVA:HIVA, suggesting a potential model for infant HIV and tuberculosis vaccination.
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.